Esther Rajavelu
Stock Analyst at UBS
(0.68)
# 3,989
Out of 4,981 analysts
26
Total ratings
46.15%
Success rate
-22.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Esther Rajavelu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Neutral | $45 → $46 | $61.10 | -24.71% | 4 | Aug 12, 2025 | |
| APLT Applied Therapeutics | Downgrades: Neutral | $13 → $2 | $0.42 | +377.21% | 3 | Dec 2, 2024 | |
| DNLI Denali Therapeutics | Maintains: Buy | $70 → $32 | $13.20 | +142.42% | 2 | Apr 9, 2024 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Buy | $141 → $215 | $461.26 | -53.39% | 5 | Oct 4, 2021 | |
| RARE Ultragenyx Pharmaceutical | Initiates: Sell | $73 | $29.02 | +151.55% | 1 | Aug 19, 2021 | |
| BHVN Biohaven | Downgrades: Neutral | $108 → $109 | $13.74 | +693.30% | 6 | Aug 10, 2021 | |
| STOK Stoke Therapeutics | Initiates: Neutral | $35 | $23.57 | +48.53% | 1 | May 18, 2021 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $174 → $228 | $125.12 | +82.23% | 1 | Mar 1, 2021 | |
| ARWR Arrowhead Pharmaceuticals | Initiates: Perform | n/a | $28.66 | - | 1 | Dec 13, 2019 | |
| INVA Innoviva | Initiates: Hold | $13 | $19.51 | -33.37% | 1 | Nov 20, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.10 | +807.28% | 1 | Jul 21, 2017 |
Ionis Pharmaceuticals
Aug 12, 2025
Maintains: Neutral
Price Target: $45 → $46
Current: $61.10
Upside: -24.71%
Applied Therapeutics
Dec 2, 2024
Downgrades: Neutral
Price Target: $13 → $2
Current: $0.42
Upside: +377.21%
Denali Therapeutics
Apr 9, 2024
Maintains: Buy
Price Target: $70 → $32
Current: $13.20
Upside: +142.42%
Alnylam Pharmaceuticals
Oct 4, 2021
Upgrades: Buy
Price Target: $141 → $215
Current: $461.26
Upside: -53.39%
Ultragenyx Pharmaceutical
Aug 19, 2021
Initiates: Sell
Price Target: $73
Current: $29.02
Upside: +151.55%
Biohaven
Aug 10, 2021
Downgrades: Neutral
Price Target: $108 → $109
Current: $13.74
Upside: +693.30%
Stoke Therapeutics
May 18, 2021
Initiates: Neutral
Price Target: $35
Current: $23.57
Upside: +48.53%
Jazz Pharmaceuticals
Mar 1, 2021
Maintains: Buy
Price Target: $174 → $228
Current: $125.12
Upside: +82.23%
Arrowhead Pharmaceuticals
Dec 13, 2019
Initiates: Perform
Price Target: n/a
Current: $28.66
Upside: -
Innoviva
Nov 20, 2017
Initiates: Hold
Price Target: $13
Current: $19.51
Upside: -33.37%
Jul 21, 2017
Initiates: Buy
Price Target: $10
Current: $1.10
Upside: +807.28%